|
|
Volumn 47, Issue 10, 2008, Pages 1311-1314
|
|
Targeted therapy for metastatic bladder cancer;Targeted-therapie des metastasierten urothelkarzinoms
a
|
|
Author keywords
Bladder cancer; Growth factor receptor; Targeted therapy
|
|
Indexed keywords
BEVACIZUMAB;
CARBOPLATIN;
CISPLATIN;
EPIDERMAL GROWTH FACTOR;
EPIDERMAL GROWTH FACTOR RECEPTOR 2;
GEFITINIB;
GEMCITABINE;
GROWTH FACTOR RECEPTOR;
IMATINIB;
LAPATINIB;
MITOGEN ACTIVATED PROTEIN KINASE;
PACLITAXEL;
RAF PROTEIN;
RAS PROTEIN;
SORAFENIB;
STEM CELL FACTOR;
TRASTUZUMAB;
BLADDER CANCER;
CANCER CHEMOTHERAPY;
CANCER STAGING;
CANCER SURVIVAL;
CARCINOMA IN SITU;
CELL MIGRATION;
CELL PROLIFERATION;
CLINICAL PROTOCOL;
HUMAN;
METASTASIS;
PROTEIN EXPRESSION;
REVIEW;
SURVIVAL TIME;
TUMOR CELL;
ANTIBODIES, MONOCLONAL;
ANTINEOPLASTIC AGENTS;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
BENZENESULFONATES;
CARCINOMA, TRANSITIONAL CELL;
DISEASE PROGRESSION;
DRUG DELIVERY SYSTEMS;
HUMANS;
PYRIDINES;
QUINAZOLINES;
RECEPTOR, ERBB-2;
RECEPTORS, GROWTH FACTOR;
SURVIVAL RATE;
URINARY BLADDER NEOPLASMS;
|
|
EID: 53249134818
PISSN: 03402592
EISSN: None
Source Type: Journal
DOI: 10.1007/s00120-008-1747-9 Document Type: Review |
|
Times cited : (3)
|
|
References (13)
|
